RARonald Alvarado-Dyer

Ronald Alvarado-Dyer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ronald Alvarado-Dyer has a total of 151 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Penetrating Brain Injury: Neurocritical Care Perspectives on the Updated Brain Trauma Foundation Guidelines

    by Ronald Alvarado-Dyer, Neeraj Badjatia, Huimahn A. Choi, Jovany Cruz, Fernando D. Goldenberg, Ali Mansour, Susanne Muehlschlegel, Kristine O’PHelan, Roy A. Poblete, Claudia Robertson, et al.

  • Open Access

    Penetrating Brain Injury: Bridging Global Disparities in Care and Advancing Management Strategies

    by Ronald Alvarado-Dyer, Ali Mansour, Roxanna Garcia, Sameera Puri, Walter Videtta, Andres Rubiano, Nicolás Ciarrochi, Elaine Lo, Farima Fakhri, Michel Torbey, et al.


  • Open Access

    Comparative Analysis of Clinical Severity and Outcomes in Penetrating Versus Blunt Traumatic Brain Injury Propensity Matched Cohorts

    by Ali Mansour, Plamena P. Powla, Ronald Alvarado-Dyer, Farima Fakhri, Paramita Das, Peleg Horowitz, Fernando D. Goldenberg, Christos Lazaridis

    Traumatic brain injury (TBI) is a global health challenge; however, penetrating brain injury (PBI) remains under-represented in evidence-based knowledge and research efforts. This study utilized data from the Trauma Quality Improvement Program (TQIP) of the National Trauma Data Bank (NTDB) to investigate outcomes of PBI as compared with clinical-severity-matched non-penetrating or blunt TBI. A total of 1765 patients with PBI were 1:1 propensity score-matched for clinical severity with blunt TBI patients. The intent of PBI was self-inflicted in 34.1% of the cases, and the mechanism was firearm-inflicted in 89.1%. Mortality was found to be significantly more common in PBI than in the severity- matched TBI cohort (33.9% vs. 14.3 %, p < 0.001) as was unfavorable outcome. Mortality was mediated by withdrawal of life-sustaining therapies (WOLST) 30% of the time, and WOLST occurred earlier (median 3 days vs. 6 days, p < 0.001) in PBI. Increased rate of mortality was observed with a Glasgow Coma Scale (GCS) of <11 in PBI as compared with <7 in blunt TBI. In conclusion, PBI patients exhibited higher mortality rates and unfavorable outcomes; one third of excess mortality was mediated by WOLST. The study also brings into question the applicability of the conventional TBI classification, based on GCS, in PBI. We emphasize the need to address the observed disparities and better understand the distinctive characteristics and mechanisms underlying PBI outcomes to improve patient care and reduce mortality.


  • Top Cited Papers

    Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study

    by Shadi Yaghi, Liqi Shu, Ekaterina Bakradze, Setareh Salehi Omran, James A. Giles, Jordan Y. Amar, Nils Henninger, Marwa Elnazeir, Ava L. Liberman, Khadean Moncrieffe, et al.

    Background: A small randomized controlled trial suggested that dabigatran may be as effective as warfarin in the treatment of cerebral venous thrombosis (CVT). We aimed to compare direct oral anticoagulants (DOACs) to warfarin in a real-world CVT cohort. Methods: This multicenter international retrospective study (United States, Europe, New Zealand) included consecutive patients with CVT treated with oral anticoagulation from January 2015 to December 2020. We abstracted demographics and CVT risk factors, hypercoagulable labs, baseline imaging data, and clinical and radiological outcomes from medical records. We used adjusted inverse probability of treatment weighted Cox-regression models to compare recurrent cerebral or systemic venous thrombosis, death, and major hemorrhage in patients treated with warfarin versus DOACs. We performed adjusted inverse probability of treatment weighted logistic regression to compare recanalization rates on follow-up imaging across the 2 treatments groups. Results: Among 1025 CVT patients across 27 centers, 845 patients met our inclusion criteria. Mean age was 44.8 years, 64.7% were women; 33.0% received DOAC only, 51.8% received warfarin only, and 15.1% received both treatments at different times. During a median follow-up of 345 (interquartile range, 140–720) days, there were 5.68 recurrent venous thrombosis, 3.77 major hemorrhages, and 1.84 deaths per 100 patient-years. Among 525 patients who met recanalization analysis inclusion criteria, 36.6% had complete, 48.2% had partial, and 15.2% had no recanalization. When compared with warfarin, DOAC treatment was associated with similar risk of recurrent venous thrombosis (aHR, 0.94 [95% CI, 0.51–1.73]; P =0.84), death (aHR, 0.78 [95% CI, 0.22–2.76]; P =0.70), and rate of partial/complete recanalization (aOR, 0.92 [95% CI, 0.48–1.73]; P =0.79), but a lower risk of major hemorrhage (aHR, 0.35 [95% CI, 0.15–0.82]; P =0.02). Conclusions: In patients with CVT, treatment with DOACs was associated with similar clinical and radiographic outcomes and favorable safety profile when compared with warfarin treatment. Our findings need confirmation by large prospective or randomized studies.


  • Open Access

    Post-Trial Enhanced Deployment and Technical Performance with the MISTIE Procedure per Lessons Learned

    by Ali Mansour, Andrea Loggini, Faten El Ammar, Ronald Alvarado-Dyer, Sean Polster, Agnieszka Stadnik, Paramita Das, Peter C. Warnke, Bakhtiar Yamini, Christos Lazaridis, et al.


  • Safer Stroke-Dx Instrument: Identifying Stroke Misdiagnosis in the Emergency Department

    by Faddi G. Saleh Velez, Ronald Alvarado-Dyer, Camila Bonin Pinto, Jorge G. Ortiz García, Daryl Mchugh, Jenny Lu, Oleg Otlivanchik, Brent L. Flusty, Ava L. Liberman, Shyam Prabhakaran

    Background: Missed or delayed diagnosis of acute stroke, or false-negative stroke (FNS), at initial emergency department (ED) presentation occurs in ≈9% of confirmed stroke patients. Failure to rapidly diagnose stroke can preclude time-sensitive treatments, resulting in higher risks of severe sequelae and disability. In this study, we developed and tested a modified version of a structured medical record review tool, the Safer Dx Instrument, to identify FNS in a subgroup of hospitalized patients with stroke to gain insight into sources of ED stroke misdiagnosis. Methods: We conducted a retrospective cohort study at 2 unaffiliated comprehensive stroke centers. In the development and confirmatory cohorts, we applied the Safer Stroke-Dx Instrument to report the prevalence and documented sources of ED diagnostic error in FNS cases among confirmed stroke patients upon whom an acute stroke was suspected by the inpatient team, as evidenced by stroke code activation or urgent neurological consultation, but not by the ED team. Inter-rater reliability and agreement were assessed using interclass coefficient and kappa values (κ). Results: Among 183 cases in the development cohort, the prevalence of FNS was 20.2% (95% CI, 15.0–26.7). Too narrow a differential diagnosis and limited neurological examination were common potential sources of error. The interclass coefficient for the Safer Stroke-Dx Instrument items ranged from 0.42 to 0.91, and items were highly correlated with each other. The κ for diagnostic error identification was 0.90 (95% CI, 0.821–0.978) using the Safer Stroke-Dx Instrument. In the confirmatory cohort of 99 cases, the prevalence of FNS was 21.2% (95% CI, 14.2–30.3) with similar sources of diagnostic error identified. Conclusions: Hospitalized patients identified by stroke codes and requests for urgent neurological consultation represent an enriched population for the study of diagnostic error in the ED. The Safer Stroke-Dx Instrument is a reliable tool for identifying FNS and sources of diagnostic error.


  • Characteristics of a Diverse Cohort of Stroke Patients with SARS-CoV-2 and Outcome by Sex

    by G. Trifan, F.D. Goldenberg, F.Z. Caprio, J. Biller, M. Schneck, A. Khaja, T. Terna, J. Brorson, C. Lazaridis, Z. Bulwa, et al.